AU2006258966B8 - Use of a cytokine from the interleukin-6 family in the preparation of a composition for combined administration with interferon-alpha - Google Patents

Use of a cytokine from the interleukin-6 family in the preparation of a composition for combined administration with interferon-alpha Download PDF

Info

Publication number
AU2006258966B8
AU2006258966B8 AU2006258966A AU2006258966A AU2006258966B8 AU 2006258966 B8 AU2006258966 B8 AU 2006258966B8 AU 2006258966 A AU2006258966 A AU 2006258966A AU 2006258966 A AU2006258966 A AU 2006258966A AU 2006258966 B8 AU2006258966 B8 AU 2006258966B8
Authority
AU
Australia
Prior art keywords
ifn
cytokine
family
pegylated
combinations
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2006258966A
Other languages
English (en)
Other versions
AU2006258966B2 (en
AU2006258966A1 (en
Inventor
Rafael Aldabe Arregui
Maria Pilar Civeira Murillo
Esther Larrea Leoz
Jesus Prieto Valtuena
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Proyecto de Biomedicina CIMA SL
Original Assignee
Proyecto de Biomedicina CIMA SL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Proyecto de Biomedicina CIMA SL filed Critical Proyecto de Biomedicina CIMA SL
Publication of AU2006258966A1 publication Critical patent/AU2006258966A1/en
Publication of AU2006258966B2 publication Critical patent/AU2006258966B2/en
Application granted granted Critical
Publication of AU2006258966B8 publication Critical patent/AU2006258966B8/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/204—IL-6
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5412—IL-6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2073—IL-11
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5415—Leukaemia inhibitory factor [LIF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5431—IL-11
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/56—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • AIDS & HIV (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pulmonology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Neurology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Dermatology (AREA)
AU2006258966A 2005-06-16 2006-06-16 Use of a cytokine from the interleukin-6 family in the preparation of a composition for combined administration with interferon-alpha Ceased AU2006258966B8 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
ESP200501468 2005-06-16
ES200501468A ES2302402B1 (es) 2005-06-16 2005-06-16 Uso de una citoquina de la familia de interleuquina-6 en la preparacion de una composicion para administracion combinada con interferon-alfa.
PCT/ES2006/000353 WO2006134195A2 (es) 2005-06-16 2006-06-16 Uso de una citoquina de la familia de interleuquina-6 en la preparación de una composición para administración combinada con interperón-alfa

Publications (3)

Publication Number Publication Date
AU2006258966A1 AU2006258966A1 (en) 2006-12-21
AU2006258966B2 AU2006258966B2 (en) 2011-11-17
AU2006258966B8 true AU2006258966B8 (en) 2011-12-08

Family

ID=37532659

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2006258966A Ceased AU2006258966B8 (en) 2005-06-16 2006-06-16 Use of a cytokine from the interleukin-6 family in the preparation of a composition for combined administration with interferon-alpha

Country Status (11)

Country Link
US (2) US7829077B2 (cg-RX-API-DMAC10.html)
EP (1) EP1905447A4 (cg-RX-API-DMAC10.html)
JP (1) JP5154412B2 (cg-RX-API-DMAC10.html)
CN (1) CN101257918B (cg-RX-API-DMAC10.html)
AU (1) AU2006258966B8 (cg-RX-API-DMAC10.html)
BR (1) BRPI0611988A2 (cg-RX-API-DMAC10.html)
CA (1) CA2612282C (cg-RX-API-DMAC10.html)
ES (1) ES2302402B1 (cg-RX-API-DMAC10.html)
MX (1) MX2007016060A (cg-RX-API-DMAC10.html)
RU (1) RU2413529C2 (cg-RX-API-DMAC10.html)
WO (1) WO2006134195A2 (cg-RX-API-DMAC10.html)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA106591C2 (uk) * 2008-07-23 2014-09-25 Тамара Алєксандровна Віткалова Спосіб лікування гепатиту с з використанням інтерферону та інтерлейкіну-1
JP2010059081A (ja) * 2008-09-02 2010-03-18 Okayama Univ オンコスタチンｍを含有する抗ｈｃｖ剤およびその利用
ES2342529B1 (es) * 2008-10-07 2011-05-11 Proyecto De Biomedicina Cima, S.L. Oncostatina m como potenciador de la actividad inmunoestimuladora de celulas epiteliales humanas.
WO2011098644A2 (es) 2010-02-09 2011-08-18 Proyecto De Biomedicina Cima, S.L. Composiciones para el tratamiento de enfermedades infecciosas y tumorales
CN109562113A (zh) 2016-05-10 2019-04-02 C4医药公司 用于靶蛋白降解的螺环降解决定子体
CN109562107A (zh) 2016-05-10 2019-04-02 C4医药公司 用于靶蛋白降解的杂环降解决定子体
CN121974842A (zh) 2016-05-10 2026-05-05 C4医药公司 用于靶蛋白降解的胺连接的c3-戊二酰亚胺降解决定子体
WO2017197046A1 (en) 2016-05-10 2017-11-16 C4 Therapeutics, Inc. C3-carbon linked glutarimide degronimers for target protein degradation
CN110636854A (zh) 2017-03-31 2019-12-31 阿卡尼斯生物技术F&E有限责任两合公司 非黑素瘤皮肤癌(nmsc)的预防和治疗
EP4717317A3 (en) 2017-06-20 2026-06-03 C4 Therapeutics, Inc. N/o-linked degrons and degronimers for protein degradation
CN113197910B (zh) * 2021-05-14 2022-09-23 苏州大学 一种基于阿司匹林及其代谢产物提高干扰素抗病毒活性的抗病毒药盒

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1988000206A1 (en) * 1986-07-08 1988-01-14 Genetics Institute, Inc. Production and use of il-6
WO1997042969A1 (en) * 1996-05-13 1997-11-20 F. Hoffmann-La Roche Ag USE OF IL-12 AND IFN-α FOR THE TREATMENT OF INFECTIOUS DISEASES
WO2000037096A2 (en) * 1998-12-22 2000-06-29 Schering Corporation Treatment of hepatitis c virus infections with interleukin-10
US6509154B1 (en) * 1997-08-04 2003-01-21 Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R.A.S.) Product comprising at least a double stranded RNA combined with at least an antiviral agent
EP0858343B1 (en) * 1995-11-02 2004-03-31 Schering Corporation Continuous low-dose cytokine infusion therapy

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6348191B1 (en) * 1986-07-08 2002-02-19 Genetics Institute, Inc. Production and use of IL-6
US6284237B1 (en) * 1986-07-08 2001-09-04 Steven C. Clark Methods of treatment using IL-6
US5372808A (en) * 1990-10-17 1994-12-13 Amgen Inc. Methods and compositions for the treatment of diseases with consensus interferon while reducing side effect
US5766582A (en) 1994-10-11 1998-06-16 Schering Corporation Stable, aqueous alfa interferon solution formulations
TW426523B (en) 1995-04-06 2001-03-21 Hoffmann La Roche Interferon solution
US5908621A (en) * 1995-11-02 1999-06-01 Schering Corporation Polyethylene glycol modified interferon therapy
EP2298900A1 (en) * 1996-09-17 2011-03-23 Novartis Vaccines and Diagnostics, Inc. Compositions and methods for treating intracellular diseases
ES2200646B1 (es) * 2001-09-21 2005-05-01 Fundacion Para La Investigacion Medica Aplicada Uso de la cardiotrofina en enfermedades hepaticas.
TW200408407A (en) * 2001-11-30 2004-06-01 Dana Farber Cancer Inst Inc Methods and compositions for modulating the immune system and uses thereof
RU2222345C2 (ru) * 2002-01-21 2004-01-27 Волчек Игорь Анатольевич Фармацевтическая композиция цитокинового и иммуномодулирующего действия
US20050027110A1 (en) * 2003-07-24 2005-02-03 Michael Russell Drug delivery in the nervous system

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1988000206A1 (en) * 1986-07-08 1988-01-14 Genetics Institute, Inc. Production and use of il-6
EP0858343B1 (en) * 1995-11-02 2004-03-31 Schering Corporation Continuous low-dose cytokine infusion therapy
WO1997042969A1 (en) * 1996-05-13 1997-11-20 F. Hoffmann-La Roche Ag USE OF IL-12 AND IFN-α FOR THE TREATMENT OF INFECTIOUS DISEASES
US6509154B1 (en) * 1997-08-04 2003-01-21 Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R.A.S.) Product comprising at least a double stranded RNA combined with at least an antiviral agent
WO2000037096A2 (en) * 1998-12-22 2000-06-29 Schering Corporation Treatment of hepatitis c virus infections with interleukin-10

Also Published As

Publication number Publication date
RU2008100307A (ru) 2009-07-27
US20090130055A1 (en) 2009-05-21
CA2612282A1 (en) 2006-12-21
JP5154412B2 (ja) 2013-02-27
WO2006134195A8 (es) 2008-01-31
BRPI0611988A2 (pt) 2010-10-13
CN101257918B (zh) 2011-09-21
RU2413529C2 (ru) 2011-03-10
WO2006134195A2 (es) 2006-12-21
EP1905447A4 (en) 2012-04-25
AU2006258966B2 (en) 2011-11-17
EP1905447A2 (en) 2008-04-02
ES2302402A1 (es) 2008-07-01
MX2007016060A (es) 2008-03-10
CN101257918A (zh) 2008-09-03
US7829077B2 (en) 2010-11-09
AU2006258966A1 (en) 2006-12-21
JP2008546672A (ja) 2008-12-25
WO2006134195A3 (es) 2007-04-19
US20110027224A1 (en) 2011-02-03
CA2612282C (en) 2014-03-25
ES2302402B1 (es) 2009-05-08

Similar Documents

Publication Publication Date Title
US20110027224A1 (en) Use of a cytokine from the interleukin-6 family in the preparation of a composition for combined administration with interferon-alpha
Frese et al. Interferon-γ inhibits replication of subgenomic and genomic hepatitis C virus RNAs
Sato et al. Antiviral response by natural killer cells through TRAIL gene induction by IFN–α/β
Preisser et al. IL‐34 and macrophage colony‐stimulating factor are overexpressed in hepatitis C virus fibrosis and induce profibrotic macrophages that promote collagen synthesis by hepatic stellate cells
Zhu et al. Novel type I interferon IL-28A suppresses hepatitis C viral RNA replication
US11576932B2 (en) Non-activated t cells expressing exogenous virus-specific T cell receptor (TCR)
Nair et al. Interferon regulatory factor-1 protects from fatal neurotropic infection with vesicular stomatitis virus by specific inhibition of viral replication in neurons
Castelruiz et al. Interferon alfa subtypes and levels of type I interferons in the liver and peripheral mononuclear cells in patients with chronic hepatitis C and controls
Ma et al. Antiviral effect of interferon lambda against West Nile virus
Ito et al. Effects of tumor necrosis factor alpha on replication of varicella-zoster virus
Martínez-Espinoza et al. Current landscape of IFN-λ: induction, inhibition, and potential clinical applications to treat respiratory viral infections
JP2008524160A (ja) インターフェロンβによるアジア人種におけるＣ型肝炎の治療
WO2002036627A2 (en) Interferons, uses and compositions related thereto
Gruber et al. Differential signaling of cmvIL‐10 through common variants of the IL‐10 receptor 1
Elemam et al. CXCL10 chemokine: a critical player in RNA and DNA viral infections. Viruses. 2022; 14: 2445
CN114404572A (zh) 一种抗SARS-CoV2病毒感染导致的细胞因子风暴的药物
Larrea et al. IFN-α 5 Mediates Stronger Tyk2-Stat-Dependent Activation and Higher Expression of 2′, 5′-Oligoadenylate Synthetase Than IFN-α 2 in Liver Cells
JP2023540175A (ja) オロチン酸カルボキシアミドトリアゾールを使用するｓａｒｓ－ｃｏｖ－２感染を処置する方法及び組成物
Lin et al. [12] TELAPREVIR (VX-950) IS A POTENT INHIBITOR OF HCV NS3 PROTEASES DERIVED FROM GENOTYPE NON-1 HCV-INFECTED PATIENTS
Chen et al. IFNA2 p. Ala120Thr impairs the inhibitory activity of Interferon-α2 against the hepatitis B virus through altering its binding to the receptor
Masihi Novel concepts for anti-infective activity of cytokines, chemokines and diverse agents
Nair et al. Interferon Regulatory Factor-1 Protects from Fatal
Masihi Progress on novel immunomodulatory agents for HIV-1 infection and other infectious diseases
Mossman Studies of Immunosuppressive Powiruses
Huang et al. [13] IN VITRO EVALUATION OF COMBINATION TREATMENT OF ACH-806 WITH INTERFERON; VX-950 AND NM 107

Legal Events

Date Code Title Description
TH Corrigenda

Free format text: IN VOL 25, NO 45, PAGE(S) 5748 UNDER THE HEADING APPLICATIONS AC- CEPTED - NAME INDEX UNDER THE NAME PROYECTO DE BIOMEDICINA CIMA, S.L., APPLICATION NO. 2006258966, UNDER INID (71) CORRECT THE APPLICANT TO READ PROYECTO DE BIOMEDICINA CIMA, S.L.

FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired